REGENXBIO Inc. (RGNX) Stock Analysis and Metrics

Regenxbio

NASDAQ: RGNX

$9.73 ▼ -0.52 (-5.02%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap501.81 Mn

P/E-11.67

P/S3.04

Div. Yield0.00

Revenue Growth (1y) (Qtr)27.97

Add ratio to table…

About

REGENXBIO is a clinical stage biotechnology company focused on developing gene therapies using adeno associated virus vectors. The company leverages its proprietary NAV Technology Platform to create investigational treatments for retinal neuromuscular and neurodegenerative diseases. REGENXBIO was founded to advance gene therapy by providing a scalable manufacturing and development platform that supports multiple therapeutic areas. Its pipeline includes product candidates for wet age related macular degeneration diabetic retinopathy Duchenne muscular dystrophy and mucopolysaccharidosis type II and type I. The company aims to deliver potentially curative one time gene therapies that could transform disease treatment.

REGENXBIO generates revenue through license agreements royalty payments and service fees from collaborations with biopharmaceutical partners. The company has received upfront payments milestone payments and royalties from partners such as Novartis Gene Therapies and Nippon Shinyaku. The AbbVie collaboration contributed an upfront payment of $370 million and the potential to receive up to $1.38 billion in milestone payments. The Nippon Shinyaku partnership provided an upfront payment of $110 million and the opportunity to earn up to $700 million in milestone payments. Additionally royalties from the Novartis license for Zolgensma and Itsvima have generated substantial revenue with reported combined sales of $1.23 billion in 2025.

REGENXBIO holds a strong position in the gene therapy sector due to its NAV Technology Platform which provides access to a large library of adeno associated virus vectors and established manufacturing expertise. The company competes with firms such as 4D Molecular Therapeutics Amicus Therapeutics Astellas Pharma BioMarin Pharmaceutical Lilly MeiraGTx Novartis Passage Bio PTC Therapeutics Roche Sanofi Sarepta Therapeutics Solid Biosciences Taysha Gene Therapies Tenaya Therapeutics Ultragenyx Pharmaceutical and uniQure. Its competitive advantages include the proprietary vector portfolio the scalable NAVXpress manufacturing process and strategic collaborations with AbbVie and Nippon Shinyaku. The company's focus on retinal neuromuscular and neurodegenerative diseases allows it to target high unmet medical needs with potentially curative one time treatments. REGENXBIO's integrated approach from research to manufacturing supports rapid advancement of candidates through clinical trials.

The company's customers include Novartis Gene Therapies and Nippon Shinyaku which together generated approximately 99% of total revenue in 2025. The Novartis relationship stems from the license for the AAV9 vector used in Zolgensma and Itsvima which have treated thousands of patients globally. Nippon Shinyaku collaborates with REGENXBIO on programs aimed at treating mucopolysaccharidosis type II and type I. AbbVie partners with the company on the development of sura vec for retinal diseases while the majority of revenue continues to come from licensing arrangements.

Investment Thesis

▲ Bull case

RGX 202 demonstrated a robust primary endpoint achievement with high statistical significance as 93% of patients exceeded the 10% microdystrophin expression threshold at week twelve. The average microdystrophin expression across the cohort reached 71% and the subset aged eight and older showed 41.6% expression marking the highest reported levels for that age group in gene therapy. Importantly the data revealed a strong statistically significant correlation between microdystrophin levels and functional improvement with correlation coefficients greater than 0.9 for both NSAA change from baseline and cTAP predicted value suggesting the biomarker could serve as a surrogate endpoint likely to predict clinical benefit. This correlation has not been observed in prior Duchenne gene therapy programs and provides a mechanistic link that reinforces confidence in the therapeutic effect of the novel construct. The functional data from nine patients showed improvement across all timed function tests and NSAA scores compared to external controls using propensity score weighting indicating a favorable trajectory relative to natural history. The consistency of these findings across age groups supports the potential for RGX 202 to modify disease progression in both younger and older ambulatory patients.
The safety profile of RGX 202 appears differentiated by a low incidence of treatment related serious adverse events with only two events observed among thirty one dosed patients both of which resolved without sequelae. One case of subacute myocarditis presented with mild chest pain and transient troponin elevation and the other was an asymptomatic liver injury identified via laboratory abnormalities both managed with a short course of steroids. No drug related thrombocytopenia myositis or neurotoxicity were reported and mean liver enzymes including GGT and total bilirubin remained stable and well below the upper limit of normal throughout the twelve month follow up. These results are achieved despite using a proactive short course immune suppression regimen that includes eculizumab and sirolimus which has remained unchanged since program inception and has been well tolerated by patients and families. The regimen addresses a major safety concern in AAV gene therapy by mitigating complement mediated and immune related adverse events that have plagued other approaches. The overall safety experience suggests a favorable benefit risk ratio that could ease physician and family apprehension about long term complications.
Near term catalysts beyond RGX 202 include the anticipated dosing of the first patient in the Phase IIb trial for diabetic retinopathy in the Q2 FY26 which would trigger a $100 million milestone payment from AbbVie under the existing collaboration agreement. Preparations are ongoing to report top line data from the subretinal pivotal studies for wet AMD and diabetic retinopathy in the Q4 FY26 providing additional data readouts that could support further partnership milestones or regulatory interactions. The partial clinical hold on RGX 121 for Hunter syndrome has been fully lifted and the company has filed an appeal of the complete response letter while continuing to engage the agency on a path forward for the program. These developments contribute to a narrative of potentially three approvals over the next couple years including two blockbuster opportunities in Duchenne and retinal diseases. The pipeline diversity reduces reliance on any single asset and provides multiple near term value inflection points.
The Duchenne market remains underserved with a growing untreated population in the United States and globally creating a clear unmet need for therapies that can alter disease progression especially in older ambulatory patients who are experiencing functional decline. RGX 202 data shows functional improvement in patients aged eight and older a demographic where natural history predicts deterioration thereby addressing a significant gap in current treatment options. Physicians and families have expressed desire for therapies that offer both efficacy and a predictable safety profile and the observed correlation between microdystrophin expression and functional benefit provides a transparent mechanistic rationale that can inform decision making. Newborn screening initiatives could further expand the addressable patient base by enabling earlier intervention before substantial muscle loss occurs. The combination of early treatment potential and demonstrable benefit in later stage patients positions RGX 202 to capture a broad segment of the Duchenne cohort.
REGENXBIO reported solid Q1 FY26 financial results that reflect a cash runway sufficient to support the ongoing confirmatory study for RGX 202 as well as the planned global activities including potential ex US randomized controlled trial discussions. The company has dosed more than fifty patients across pivotal and confirmatory studies with line of sight to sixty patients by mid year 2026 providing a growing safety database that will exceed fifty patients by the time of a potential early 2027 BLA filing. This expanding safety base mitigates concerns about limited sample size and strengthens the regulatory submission. In addition partnership milestones from AbbVie and potential royalties from approved retinal therapies could contribute to future revenue streams reducing dilution risk and supporting continued investment in pipeline programs.

RGX 202 demonstrated a robust primary endpoint achievement with high statistical significance as 93% of patients exceeded the 10% microdystrophin expression threshold at week twelve. The average microdystrophin expression across the cohort reached 71% and the subset aged eight and older showed 41.6% expression marking the highest reported levels for that age group in gene therapy. Importantly the data revealed a strong statistically significant correlation between microdystrophin levels and functional improvement with correlation coefficients greater than 0.9 for both NSAA change from baseline and cTAP predicted value suggesting the biomarker could serve as a surrogate endpoint likely to predict clinical benefit. This correlation has not been observed in prior Duchenne gene therapy programs and provides a mechanistic link that reinforces confidence in the therapeutic effect of the novel construct. The functional data from nine patients showed improvement across all timed function tests and NSAA scores compared to external controls using propensity score weighting indicating a favorable trajectory relative to natural history. The consistency of these findings across age groups supports the potential for RGX 202 to modify disease progression in both younger and older ambulatory patients.
The safety profile of RGX 202 appears differentiated by a low incidence of treatment related serious adverse events with only two events observed among thirty one dosed patients both of which resolved without sequelae. One case of subacute myocarditis presented with mild chest pain and transient troponin elevation and the other was an asymptomatic liver injury identified via laboratory abnormalities both managed with a short course of steroids. No drug related thrombocytopenia myositis or neurotoxicity were reported and mean liver enzymes including GGT and total bilirubin remained stable and well below the upper limit of normal throughout the twelve month follow up. These results are achieved despite using a proactive short course immune suppression regimen that includes eculizumab and sirolimus which has remained unchanged since program inception and has been well tolerated by patients and families. The regimen addresses a major safety concern in AAV gene therapy by mitigating complement mediated and immune related adverse events that have plagued other approaches. The overall safety experience suggests a favorable benefit risk ratio that could ease physician and family apprehension about long term complications.
Near term catalysts beyond RGX 202 include the anticipated dosing of the first patient in the Phase IIb trial for diabetic retinopathy in the Q2 FY26 which would trigger a $100 million milestone payment from AbbVie under the existing collaboration agreement. Preparations are ongoing to report top line data from the subretinal pivotal studies for wet AMD and diabetic retinopathy in the Q4 FY26 providing additional data readouts that could support further partnership milestones or regulatory interactions. The partial clinical hold on RGX 121 for Hunter syndrome has been fully lifted and the company has filed an appeal of the complete response letter while continuing to engage the agency on a path forward for the program. These developments contribute to a narrative of potentially three approvals over the next couple years including two blockbuster opportunities in Duchenne and retinal diseases. The pipeline diversity reduces reliance on any single asset and provides multiple near term value inflection points.
The Duchenne market remains underserved with a growing untreated population in the United States and globally creating a clear unmet need for therapies that can alter disease progression especially in older ambulatory patients who are experiencing functional decline. RGX 202 data shows functional improvement in patients aged eight and older a demographic where natural history predicts deterioration thereby addressing a significant gap in current treatment options. Physicians and families have expressed desire for therapies that offer both efficacy and a predictable safety profile and the observed correlation between microdystrophin expression and functional benefit provides a transparent mechanistic rationale that can inform decision making. Newborn screening initiatives could further expand the addressable patient base by enabling earlier intervention before substantial muscle loss occurs. The combination of early treatment potential and demonstrable benefit in later stage patients positions RGX 202 to capture a broad segment of the Duchenne cohort.
REGENXBIO reported solid Q1 FY26 financial results that reflect a cash runway sufficient to support the ongoing confirmatory study for RGX 202 as well as the planned global activities including potential ex US randomized controlled trial discussions. The company has dosed more than fifty patients across pivotal and confirmatory studies with line of sight to sixty patients by mid year 2026 providing a growing safety database that will exceed fifty patients by the time of a potential early 2027 BLA filing. This expanding safety base mitigates concerns about limited sample size and strengthens the regulatory submission. In addition partnership milestones from AbbVie and potential royalties from approved retinal therapies could contribute to future revenue streams reducing dilution risk and supporting continued investment in pipeline programs.

▼ Bear case

The functional dataset supporting RGX 202 remains limited to nine patients with twelve month outcome data which is a relatively small sample size for drawing definitive conclusions about long term efficacy. Although the demographics of these nine patients mirror the overall trial population the small number increases the risk that the observed functional benefit could be driven by chance or by a subset of particularly responsive individuals. As enrollment continues and more patients reach the twelve month mark there is potential for the treatment effect to attenuate or for safety signals to emerge that were not apparent in the early cohort. The reliance on external controls via propensity score weighting while methodologically sound introduces uncertainty because any unmeasured confounders could bias the comparison against natural history data. Investors should be cautious about extrapolating the current efficacy signal to the broader Duchenne population without larger longitudinal data.
Two treatment related serious adverse events were observed in the trial including a case of subacute myocarditis and an asymptomatic liver injury requiring steroid intervention indicating that organ specific toxicity can occur despite the proactive immune suppression regimen. While both events resolved without sequelae they highlight that the therapy is not free of significant safety concerns and that longer term follow up is needed to monitor for potential delayed cardiac or hepatic complications. The liver injury event occurred despite stable mean liver enzymes across the cohort suggesting that individual susceptibility may play a role and that broader use could uncover a higher incidence of clinically relevant hepatotoxicity. The myocarditis case raises questions about cardiac safety particularly in patients with pre existing cardiac vulnerability which may not be fully captured in the short term safety data. These safety observations could influence payer coverage decisions and physician prescribing habits especially if longer term data reveal higher rates of adverse events.
Regulatory discussions have signaled that the FDA may still require a randomized controlled trial as part of the confirmatory study package for accelerated approval any such requirement would likely delay approval until the early 2030s given the time needed to design enroll and complete an RCT in a rare disease setting. The company has acknowledged that completing an RCT as a precursor to filing would make approval unlikely before 2030 which contrasts sharply with the optimistic 2027 timeline predicated on the external control strategy and biomarker surrogate. If the agency insists on a randomized design the therapeutic commercialization window would be compressed reducing net present value and potentially allowing competitors to capture market share. The uncertainty around the FDA stance creates a significant overhang on the near term valuation of RGX 202.
Manufacturing AAV gene therapies at the scale needed for widespread Duchenne treatment presents challenges related to vector copy number control product purity and cost of goods. The high vector copy numbers observed in the trial while supportive of efficacy may also raise concerns about dose related toxicity especially if manufacturing variability leads to higher than intended doses in commercial lots. The complexity of the production process could result in supply constraints or batch failures that would disrupt launch plans and increase per patient pricing pressure. Reimbursement for a one time high cost gene therapy remains uncertain particularly in markets with strict cost effectiveness thresholds and payers may demand long term durability data before granting broad coverage. These commercialization hurdles could limit the realizable price and uptake of RGX 202 even if regulatory approval is obtained.
Competition in the Duchenne space is intensifying with several gene therapy programs exon skipping approaches and emerging CRISPR based editing strategies advancing through clinical trials. Some competitors may offer alternative safety profiles lower dosing requirements or more established manufacturing platforms which could attract physicians and patients seeking a perceived advantage. If a rival therapy demonstrates comparable efficacy with a simpler immunosuppressive regimen or a better long term safety record RGX 202 could face pressure on pricing and market share. Additionally the evolution of standard of care corticosteroids and emerging exon skipping therapies may shift the treatment paradigm reducing the incremental value proposition of a novel microdystrophin construct. The company must continue to differentiate its offering not only on biomarker function correlation but also on practical considerations such as dosing convenience and durability.

The functional dataset supporting RGX 202 remains limited to nine patients with twelve month outcome data which is a relatively small sample size for drawing definitive conclusions about long term efficacy. Although the demographics of these nine patients mirror the overall trial population the small number increases the risk that the observed functional benefit could be driven by chance or by a subset of particularly responsive individuals. As enrollment continues and more patients reach the twelve month mark there is potential for the treatment effect to attenuate or for safety signals to emerge that were not apparent in the early cohort. The reliance on external controls via propensity score weighting while methodologically sound introduces uncertainty because any unmeasured confounders could bias the comparison against natural history data. Investors should be cautious about extrapolating the current efficacy signal to the broader Duchenne population without larger longitudinal data.
Two treatment related serious adverse events were observed in the trial including a case of subacute myocarditis and an asymptomatic liver injury requiring steroid intervention indicating that organ specific toxicity can occur despite the proactive immune suppression regimen. While both events resolved without sequelae they highlight that the therapy is not free of significant safety concerns and that longer term follow up is needed to monitor for potential delayed cardiac or hepatic complications. The liver injury event occurred despite stable mean liver enzymes across the cohort suggesting that individual susceptibility may play a role and that broader use could uncover a higher incidence of clinically relevant hepatotoxicity. The myocarditis case raises questions about cardiac safety particularly in patients with pre existing cardiac vulnerability which may not be fully captured in the short term safety data. These safety observations could influence payer coverage decisions and physician prescribing habits especially if longer term data reveal higher rates of adverse events.
Regulatory discussions have signaled that the FDA may still require a randomized controlled trial as part of the confirmatory study package for accelerated approval any such requirement would likely delay approval until the early 2030s given the time needed to design enroll and complete an RCT in a rare disease setting. The company has acknowledged that completing an RCT as a precursor to filing would make approval unlikely before 2030 which contrasts sharply with the optimistic 2027 timeline predicated on the external control strategy and biomarker surrogate. If the agency insists on a randomized design the therapeutic commercialization window would be compressed reducing net present value and potentially allowing competitors to capture market share. The uncertainty around the FDA stance creates a significant overhang on the near term valuation of RGX 202.
Manufacturing AAV gene therapies at the scale needed for widespread Duchenne treatment presents challenges related to vector copy number control product purity and cost of goods. The high vector copy numbers observed in the trial while supportive of efficacy may also raise concerns about dose related toxicity especially if manufacturing variability leads to higher than intended doses in commercial lots. The complexity of the production process could result in supply constraints or batch failures that would disrupt launch plans and increase per patient pricing pressure. Reimbursement for a one time high cost gene therapy remains uncertain particularly in markets with strict cost effectiveness thresholds and payers may demand long term durability data before granting broad coverage. These commercialization hurdles could limit the realizable price and uptake of RGX 202 even if regulatory approval is obtained.
Competition in the Duchenne space is intensifying with several gene therapy programs exon skipping approaches and emerging CRISPR based editing strategies advancing through clinical trials. Some competitors may offer alternative safety profiles lower dosing requirements or more established manufacturing platforms which could attract physicians and patients seeking a perceived advantage. If a rival therapy demonstrates comparable efficacy with a simpler immunosuppressive regimen or a better long term safety record RGX 202 could face pressure on pricing and market share. Additionally the evolution of standard of care corticosteroids and emerging exon skipping therapies may shift the treatment paradigm reducing the incremental value proposition of a novel microdystrophin construct. The company must continue to differentiate its offering not only on biomarker function correlation but also on practical considerations such as dosing convenience and durability.

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Consolidation Items Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password